ACET

ANALYST NOTE: ACET (Adicet Bio, Inc.) Date: 2026-06-13 Current Price: $8.10

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $8.10 Extension: — ATR at Breakout: — ATR Current: 8.6% (Extreme) Pivot Strength: —

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None Named

There is no named secular thesis attached to this name as of this date. This is a tactical, setup-led name. The conviction must be derived strictly from the quality of the technical structure (the forming coil) and the specific business fundamentals disclosed in the evidence base. No macro or industry-wide tailwinds are being assumed or invented for this analysis. The investment case rests entirely on the execution of the company's specific clinical milestones and the structural resolution of the current price consolidation.

3. Business Overview

Company Profile: Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's business model is high-risk, high-reward R&D, relying on the successful execution of clinical trials and subsequent regulatory approvals to generate future sales.

Key Business Activities & Evidence (as of 2026-06-13):

• Core Asset (Prula-cel): The company's business is highly dependent on the success of prula-cel (formerly ADI-001), an allogeneic gamma delta T cell therapy.
• *Evidence:* Management expects operating losses and negative cash flows to continue for the foreseeable future until significant sales are generated (E15).
• *Clinical Status:* In October 2025, the company announced positive preliminary results from seven SLE and LN patients dosed in the ongoing Phase 1 trial (E17).
• *Future Plans:* Management plans to meet with the FDA in Q2 2026 to inform potential pivotal trial design. Subject to regulatory clearance, they expect to initiate a potential pivotal study in Lupus Nephritis (LN) or LN and Systemic Lupus Erythematosus (SLE) patients in the second half of 2026 (E18).
• Secondary Asset (ADI-212): A CAR T cell therapy directed against Glypican-3 for metastatic castration-resistant prostate cancer (mCRPC).
• *Evidence:* Management expects to submit a regulatory filing (IND) for ADI-212 in Q3 2026 and initiate patient enrollment in Q4 2026, subject to clearance (E19).
• Strategic Partnerships:
• *Evidence:* On January 28, 2022, Regeneron exercised its option to license exclusive worldwide rights to ADI-002 (E16).
• Financial Position:
• *Evidence:* Management explicitly states, "We will need substantial additional financing to develop our product candidates and implement our operating plans" (E14).
• *Evidence:* The company is highly dependent on the success of prula-cel (E12).

Industry Context: The company operates in the biotechnology sector, specifically within the emerging field of allogeneic CAR-T therapies for autoimmune indications. Management notes that while approved therapies for autoimmune diseases treat symptoms chronically, CAR-T therapy has the potential to remove disease-causing immune cells with a single dose, offering a potential curative effect (E23).

4. Archetype and Conviction

Archetype: Quality Compounder (Source: Layer A) Fit Analysis: The "Quality Compounder" archetype is applied here based on the company's strategic positioning in a novel therapeutic modality (allogeneic gamma delta T cells) and the potential for significant market expansion in autoimmune diseases (1.7M+ patients) and oncology (75,000+ patients in mCRPC) (E21, E22). The archetype fits the *potential* of the business model if clinical execution succeeds, rather than current financial performance, which is characterized by losses and negative cash flow (E15).

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Moderate. The evidence base is robust regarding clinical milestones and management expectations (E9-E24), but the financial evidence points to a cash-burn scenario requiring external financing (E14).
• Structural Quality: Mixed. The setup is "Forming," which is a positive structural signal (69% historical breakout rate for forming coils), but the "Extreme" ATR (8.6%) is a significant negative structural factor, historically correlating with severe downside risk.
• Rerating Potential: High, contingent on the Q2 2026 FDA meeting and the initiation of the pivotal trial in H2 2026.

Valuation Context: No specific valuation multiples are provided in the evidence base. The company is pre-revenue for its core assets, and management expects losses to continue. The current price of $8.10 reflects the market's pricing of binary clinical risk and the need for additional financing.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Failure to secure the "substantial additional financing" required to continue operations (E14), or a negative outcome from the FDA meeting in Q2 2026 that prevents the initiation of the pivotal trial.
• Clinical: Disappointing data from the ongoing Phase 1 trial updates expected in H1 2026 (E20).

What Would Strengthen the Case:

• Fundamental: Positive data readouts from the Phase 1 trial (E17) leading to a clear path for the pivotal trial, or a successful financing round that extends the cash runway.
• Strategic: New partnership announcements similar to the Regeneron deal (E16).

Gaps in Evidence Base:

• Cash Runway: While management states they need financing (E14), the specific amount of cash on hand and the exact burn rate as of Q2 2026 are not detailed in the provided evidence.
• Dilution Risk: The need for "substantial additional financing" implies significant dilution risk, but the specific terms or potential impact on share count are not quantified.
• Competitive Landscape: While the market opportunity is defined (E21, E22), there is no evidence provided regarding specific competitive threats or the company's differentiation beyond the mechanism of action.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Extreme ATR of 8.6% indicates high volatility and severe loser potential; Binary clinical risk with no revenue; High probability of dilution due to financing needs. Sizing hint: Position size must be minimal due to extreme volatility and binary nature of catalysts. Expected path: Price likely to remain range-bound or volatile until the Q2 2026 FDA meeting results are known, with potential for a breakout if pivotal trial initiation is confirmed. Expected horizon: 3 to 6 months (until H2 2026 pivotal trial initiation or data readout).